C Oliver Hanemann Selected Research

Neurofibromin 2 (Merlin)

1/2022	Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma.
6/2020	The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma.
2/2017	Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.
1/2017	Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.
1/2017	An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
7/2014	Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
4/2013	Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy.
2/2013	Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells.
11/2012	The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
5/2012	Merlin, a multi-suppressor from cell membrane to the nucleus.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

C Oliver Hanemann Research Topics

Disease

24	Neoplasms (Cancer) 01/2022 - 06/2003
19	Neurilemmoma (Schwannoma) 01/2022 - 06/2003
16	Meningioma (Meningiomas) 01/2022 - 07/2003
15	Neurofibromatosis 2 (Neurofibromatosis Type II) 01/2022 - 07/2003
6	Carcinogenesis 01/2022 - 02/2010
5	Ependymoma 01/2022 - 01/2010
4	Neurofibromatoses (Neurofibromatosis) 08/2016 - 04/2005
4	Schwannomatosis 08/2016 - 03/2012
4	Nervous System Neoplasms (Neoplasms, Nervous System) 11/2012 - 01/2009
3	Neurofibromatosis 1 (Neurofibromatosis Type I) 08/2016 - 01/2004
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 11/2012
2	Neurofibrosarcoma (MPNST) 01/2020 - 04/2005
2	Glioma (Gliomas) 03/2012 - 06/2005
2	Neurofibroma 03/2012 - 04/2005
1	Sarcoma (Soft Tissue Sarcoma) 01/2020
1	Malignant Mesothelioma 01/2017
1	Mitochondrial Diseases (Mitochondrial Disease) 07/2016
1	Neuroblastoma 07/2016
1	Parkinson Disease (Parkinson's Disease) 07/2016
1	Respiratory Insufficiency (Respiratory Failure) 01/2016
1	Deglutition Disorders (Dysphagia) 12/2013
1	Polyneuropathies (Polyneuropathy) 04/2013
1	Multiple Sclerosis 09/2011
1	Acoustic Neuroma (Acoustic Neurinoma) 08/2010

Drug/Important Bio-Agent (IBA)

23	Neurofibromin 2 (Merlin)IBA 01/2022 - 06/2003
15	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2003
7	Biomarkers (Surrogate Marker)IBA 12/2021 - 11/2013
6	Pharmaceutical PreparationsIBA 11/2012 - 04/2005
5	Phosphotransferases (Kinase)IBA 07/2014 - 01/2004
4	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 06/2016 - 07/2008
3	EnzymesIBA 01/2021 - 01/2017
3	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2017 - 02/2010
3	IntegrinsIBA 08/2011 - 07/2003
3	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 06/2011 - 06/2003
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 06/2020
2	fibulin 2IBA 12/2021 - 01/2021
2	RNA (Ribonucleic Acid)IBA 11/2020 - 02/2019
2	ProteomeIBA 11/2020 - 02/2017
2	Transcription Factors (Transcription Factor)IBA 09/2020 - 02/2013
2	AZD 6244IBA 06/2020 - 01/2010
2	Sorafenib (BAY 43-9006)FDA Link 10/2019 - 07/2008
2	Growth Factor ReceptorsIBA 06/2016 - 07/2008
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2016 - 07/2008
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2016 - 06/2011
2	Messenger RNA (mRNA)IBA 02/2013 - 06/2003
2	Insulin-Like PeptidesIBA 11/2012 - 06/2011
2	tyrosine receptor (receptor, tyrosine)IBA 06/2011 - 08/2010
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2010 - 07/2008
2	MitogensIBA 01/2010 - 07/2008
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2022
1	Ritonavir (Norvir)FDA Link 01/2022
1	Atazanavir Sulfate (Reyataz)FDA Link 01/2022
1	Lopinavir FDA Link 01/2022
1	Glycoproteins (Glycoprotein)IBA 01/2021
1	CalciumIBA 01/2021
1	ImmunosorbentsIBA 01/2021
1	MicroRNAs (MicroRNA)IBA 09/2020
1	Cyclin D1IBA 09/2020
1	Carrier Proteins (Binding Protein)IBA 09/2020
1	Cullin Proteins (Cullins)IBA 06/2020
1	CateninsIBA 01/2020
1	Cytostatic AgentsIBA 01/2020
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2020
1	RNA Splicing FactorsIBA 02/2019
1	PhosphopeptidesIBA 02/2019
1	PhosphoproteinsIBA 02/2019
1	Small Interfering RNA (siRNA)IBA 02/2017
1	1- (4- ((2- (2- aminopyrimidin- 5- yl)- 7- methyl- 4- morpholinothieno(3,2- d)pyrimidin- 6- yl)methyl)piperazin- 1- yl)- 2- hydroxypropan- 1- oneIBA 01/2017
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2017
1	pevonedistatIBA 01/2017
1	Malonyl Coenzyme A (Malonyl CoA)IBA 01/2017
1	Long-Acting Thyroid Stimulator (LATS)IBA 01/2017
1	Uvitex SWN (SWN)IBA 08/2016
1	Pioglitazone (Actos)FDA Link 07/2016
1	1-Methyl-4-phenylpyridinium (1 Methyl 4 phenylpyridinium)IBA 07/2016
1	IodidesIBA 07/2016
1	LigandsIBA 06/2016
1	Somatomedin Receptors (Somatomedin Receptor)IBA 06/2016
1	hydroxide ionIBA 01/2016
1	Riluzole FDA LinkGeneric 01/2016
1	Mitogen-Activated Protein KinasesIBA 01/2015
1	Botulinum Toxins (Botulinum Toxin)IBA 12/2013
1	Protein Isoforms (Isoforms)IBA 04/2013
1	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 02/2013
1	Insulin-Like Growth Factor I (IGF-1)IBA 11/2012
1	IGF Type 1 Receptor (IGF 1 Receptor)IBA 11/2012
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 09/2011
1	Phospholipase DIBA 09/2011
1	phosphatidylethanolamineIBA 09/2011
1	CannabinoidsIBA 09/2011
1	ezrinIBA 08/2011
1	radixinIBA 08/2011
1	moesinIBA 08/2011
1	Lapatinib (GW572016)FDA Link 08/2010
1	Platelet-Derived Growth FactorIBA 01/2010

Therapy/Procedure

9	Therapeutics 01/2017 - 01/2004
4	Drug Therapy (Chemotherapy) 09/2020 - 01/2010
3	Radiotherapy 01/2022 - 06/2011
1	Immunotherapy 02/2020
1	Noninvasive Ventilation 01/2016